See more : National Bank of Greece S.A. (NBGIF) Income Statement Analysis – Financial Results
Complete financial analysis of Alector, Inc. (ALEC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alector, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- SSAB AB (publ) (SSABAH.HE) Income Statement Analysis – Financial Results
- Johnson & Johnson (JNJ) Income Statement Analysis – Financial Results
- Eco Science Solutions, Inc. (ESSI) Income Statement Analysis – Financial Results
- Seven Oaks Acquisition Corp. (SVOK) Income Statement Analysis – Financial Results
- Personalis, Inc. (PSNL) Income Statement Analysis – Financial Results
Alector, Inc. (ALEC)
About Alector, Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 97.06M | 133.62M | 207.09M | 21.10M | 21.22M | 27.68M | 3.74M | 416.00K |
| Cost of Revenue | 192.12M | 8.47M | 189.41M | 156.87M | 100.53M | 73.03M | 29.91M | 13.67M |
| Gross Profit | -95.05M | 125.15M | 17.68M | -135.77M | -79.31M | -45.35M | -26.18M | -13.26M |
| Gross Profit Ratio | -97.93% | 93.66% | 8.54% | -643.53% | -373.76% | -163.87% | -700.83% | -3,187.02% |
| Research & Development | 192.12M | 210.42M | 189.41M | 156.87M | 100.53M | 73.03M | 29.91M | 13.67M |
| General & Administrative | 56.69M | 61.03M | 55.04M | 59.40M | 35.10M | 11.93M | 6.50M | 1.87M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 56.69M | 61.03M | 55.04M | 59.40M | 35.10M | 11.93M | 6.50M | 1.87M |
| Other Expenses | 0.00 | 7.78M | 1.03M | 4.95M | 9.02M | 5.04M | 199.00K | 22.00K |
| Operating Expenses | 248.80M | 271.45M | 244.45M | 216.27M | 135.62M | 84.97M | 36.41M | 15.55M |
| Cost & Expenses | 248.80M | 271.45M | 244.45M | 216.27M | 135.62M | 84.97M | 36.41M | 15.55M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.85M | 8.47M | 8.31M | 7.27M | 5.57M | 1.02M | 680.00K | 201.00K |
| EBITDA | -142.89M | -129.36M | -29.05M | -187.91M | -109.47M | -56.27M | -32.00M | -14.93M |
| EBITDA Ratio | -147.22% | -103.16% | -18.04% | -925.08% | -539.16% | -206.99% | -856.73% | -3,589.18% |
| Operating Income | -151.74M | -137.83M | -37.36M | -195.17M | -114.40M | -57.29M | -32.68M | -15.13M |
| Operating Income Ratio | -156.33% | -103.16% | -18.04% | -925.08% | -539.16% | -206.99% | -874.94% | -3,637.50% |
| Total Other Income/Expenses | 26.56M | 7.78M | 1.03M | 4.95M | 9.02M | 5.04M | 199.00K | 22.00K |
| Income Before Tax | -125.18M | -130.06M | -36.33M | -190.23M | -105.39M | -52.25M | -32.48M | -15.11M |
| Income Before Tax Ratio | -128.97% | -97.33% | -17.54% | -901.64% | -496.65% | -188.78% | -869.61% | -3,632.21% |
| Income Tax Expense | 5.21M | 3.25M | -8.32M | -7.27M | -5.57M | 5.04M | 0.00 | 0.00 |
| Net Income | -130.39M | -133.31M | -28.01M | -182.96M | -99.81M | -52.25M | -32.48M | -15.11M |
| Net Income Ratio | -134.34% | -99.77% | -13.53% | -867.21% | -470.39% | -188.78% | -869.61% | -3,632.21% |
| EPS | -1.56 | -1.62 | -0.35 | -2.35 | -1.62 | -0.76 | -0.63 | -0.29 |
| EPS Diluted | -1.56 | -1.62 | -0.35 | -2.35 | -1.62 | -0.76 | -0.63 | -0.29 |
| Weighted Avg Shares Out | 83.73M | 82.47M | 80.42M | 77.76M | 61.73M | 68.37M | 51.22M | 51.22M |
| Weighted Avg Shares Out (Dil) | 83.73M | 82.47M | 80.42M | 77.76M | 61.73M | 68.37M | 51.22M | 51.22M |
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
The Dot Group, the Leader in Global Student Living, Announces Its Board of Directors and New Chief Operating Officer
Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
Houlihan Lokey Hires Alec Ellison to Lead New FinTech Group
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update
iHeartMedia Launches New Outspoken Podcast Network to Spotlight LGBTQ+ Voices
Panish | Shea | Boyle | Ravipudi LLP Obtains $200 Million Judgment Against Drunk Driver Responsible for Death of Musician Noah Benardout
Immune-Onc Therapeutics to Showcase Leadership in Myeloid Biology and Drug Development at Upcoming Scientific and Investor Conferences
Source: https://incomestatements.info
Category: Stock Reports